Alexandra(Kroeger)ThomasMD

Oncology • Durham, NC

Breast Cancer, Hematologic Oncology

Professor of Internal Medicine

Join to view full profile

Dr. Thomas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thomas' full profile

Already have an account?

Office
10 Duke Medical Circle
Durham, NC 27710

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2006 - 2008
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1995 - 1998
Johns Hopkins University School of MedicineClass of 1995

Certifications & Licensure

NC State Medical License 2016 - 2025
IA State Medical License 1998 - 2019
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
NR in Chemo-induced Peripheral Neuropathy Start of enrollment: 2019 Nov 08
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.
Alexandra Thomas, Erica L Mayer, Angela DeMichele, Nadia Harbeck, Giuseppe Curigliano
Journal of Clinical Oncology. 2024-10-09
Correction: Regua et al. TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-En...
Angelina T Regua, Noah R Aguayo, Sara Abu Jalboush, Daniel L Doheny, Sara G Manore
Cancers. 2024-10-08
Optimizing Therapy to Match the Risk: Neoadjuvant Approaches to Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Alexandra Thomas, Amanda Broderick, Carey K Anders
JCO Oncology Practice. 2024-08-01

Press Mentions

Breast Cancer Amongst Young WomenOctober 22nd, 2024
Early Puberty May Contribute to Increase in Breast Cancer Among Younger WomenOctober 19th, 2024
‘Heretical’ Idea for Treating Triple-Negative Breast Cancer Moves ForwardOctober 15th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member